Literature DB >> 32343743

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.

Luca Schifanella, Susan W Barnett, Massimiliano Bissa, Veronica Galli, Melvin N Doster, Monica Vaccari, Georgia D Tomaras, Xiaoying Shen, Sanjay Phogat, Ranajit Pal, David C Montefiori, Celia C LaBranche, Mangala Rao, Hung V Trinh, Robyn Washington-Parks, Namal P M Liyanage, Giacomo Gorini, Dallas R Brown, Frank Liang, Karin Loré, David J Venzon, William Magnanelli, Michelle Metrinko, Josh Kramer, Matthew Breed, Galit Alter, Ruth M Ruprecht, Genoveffa Franchini.   

Abstract

[This corrects the article DOI: 10.1371/journal.ppat.1008121.].

Entities:  

Year:  2020        PMID： 32343743      PMCID： PMC7188203          DOI： 10.1371/journal.ppat.1008531

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN： 1553-7366            Impact factor:   6.823


  1 in total

1.  ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.

Authors:  Luca Schifanella; Susan W Barnett; Massimiliano Bissa; Veronica Galli; Melvin N Doster; Monica Vaccari; Georgia D Tomaras; Xiaoying Shen; Sanjay Phogat; Ranajit Pal; David C Montefiori; Celia C LaBranche; Mangala Rao; Hung V Trinh; Robyn Washington-Parks; Namal P M Liyanage; Giacomo Gorini; Dallas R Brown; Frank Liang; Karin Loré; David J Venzon; William Magnanelli; Michelle Metrinko; Josh Kramer; Matthew Breed; Galit Alter; Ruth M Ruprecht; Genoveffa Franchini
Journal:  PLoS Pathog       Date:  2019-12-03       Impact factor: 6.823
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.